Regeneron announces $4.07 billion in 2018 US net sales for Eylea®

Jan 7, 2019

Regeneron announces $4.07 billion in 2018 US net sales for Eylea®, as it awaits the commencement of new clinical trials for a high dose formulation.  Additionally, the FDA has assigned 13 May 19 as the action date for a potential new indication in diabetic retinopathy.

Print Page Mail Article